Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer …

ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more

Estimated

~$10 – $8,750

Nuvectis Pharma, Inc.NCT07784959